Secukinumab
monoclonal antibody against IL-17 used for treatment of psoriasis
Secukinumab, sold under the brand name Cosentyx among others, is a human IgG1κ monoclonal antibody used for the treatment of psoriasis, ankylosing spondylitis, psoriatic arthritis, and hidradenitis suppurativa. It binds to the protein interleukin (IL)-17A and is marketed by Novartis.
Medical uses
Secukinumab is used to treat psoriasis, ankylosing spondylitis, psoriatic arthritis, and hidradenitis suppurativa. It is given by subcutaneous injection and is sold in a pre-filled syringe or autoinjector that can be used at home and as a lyophilized powder for use in hospitals and clinics. In October 2023, the FDA approved an intravenous variant of secukinumab.
Secukinumab was not tested in pregnant women; animal studies did not show harm at relevant doses. The US Food and Drug Administration advises that the drug should be used in pregnant women only if the risk to the fetus is justified by the potential benefit; the European Medicines Agency (EMA) advises that women should not become pregnant while taking it.
In the European Union, secukinumab is indicated for the treatment of:
moderate to severe plaque psoriasis in adults, children and adolescents from the age of six years who are candidates for systemic therapy.
active psoriatic arthritis in adults, alone or in combination with methotrexate (MTX), when the response to previous disease modifying anti rheumatic drug (DMARD) therapy has been inadequate.
active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.
“Secukinumab” enters the record as monoclonal antibody against IL-17 used for treatment of psoriasis. Crown Archives preserves that source wording while asking what Secukinumab, monoclonal and antibody can confirm, complicate or overturn.
Why this record matters
“Secukinumab” is worth following because a concise public description often conceals a longer documentary argument. Here, Secukinumab, monoclonal and antibody provides the most credible route into that argument.
Named sources, stable identifiers and responsible institutions provide the strongest route from overview to verifiable evidence. The source revision retrieved here is dated May 2, 2026. The linked authority identifier is Q7444755. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2023.
Overview language is designed for orientation and should not be treated as a substitute for the evidence cited beneath it. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “Secukinumab”, its source revision and the description used here.
- Expand the search: follow Secukinumab primary sources, Secukinumab archive and Secukinumab research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Secukinumab”?
- Which cited source is closest to the event, object or claim?
- Which institution is responsible for the underlying evidence?
Search terms from this dossier
This entry incorporates text from “Secukinumab” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.